22.09.2021
Cerenion awarded a key patent on its C-Trend® technology in China
The National Intellectual Property Administration of the P.R.C. (CNIPA) has awarded Cerenion its first patent on C-Trend® in China.
Cerenion's patented technology represents the world’s first practical method for measuring the brain function of intensive care patients. The Cerenion C-Trend® reveals the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient. The new patent represents a significant expansion of the protection for the technology on a major future market.
"We are thrilled to receive this key patent and look forward to making our technology available in China", remarks Dr. Jukka Kortelainen, CEO at Cerenion.
Cerenion has filed multiple intellectual property applications on its technology worldwide. So far it has been granted patents in, for example, the European Union, the United States, and Japan.
Highlights
This website and all of the content therein is for reference purposes only and is not intended to substitute for advice from a licensed healthcare professional. Not available in the United States. Cerenion™, Cerenion C-Trend™, C-Trend™, "The next-generation brain monitoring company"™ and "The pulse of the brain"™ are registered trademarks and/or trademarks of Cerenion Oy. Cerenion C-Trend™ is intended for use by qualified medical practitioners who will exercise professional judgment in its use. Cerenion technology is protected by Intellectual Property Rights. Patents pending worldwide. All rights reserved. © Cerenion Oy 2020.